Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

22 mai 2018

09:30
Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to zolpidem ER (exploratory endpoint) Next-morning driving...

09:29
Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related conditions, announced that it has received a $750,000 grant from the Maryland Technology Development Corporation (TEDCO).  Longeveron will apply the...

09:03
Edwards Lifesciences Corporation , the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450...

09:00
Envisagenics, Inc., a New York based biotechnology company, announced today that it was awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH). This grant will provide $1.5 million over two...

08:30
On Thursday, May 17, Janssen announced the termination of the EARLY clinical trial investigating a BACE inhibitor, atabecestat. The goal of this research was to slow cognitive decline in people at risk of Alzheimer's dementia....

08:30
Ampio Pharmaceuticals, Inc. today announced a poster presentation on the mechanism of action of a component of Ampiontm will be presented at AAST and the most recent study of Ampion treatment of Severe Osteoarthritis of the Knee ( AP-007-B) has been...

08:30
Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful first-in-human implantation of its Alivio ReFlowtm Ventricular System for treatment of...

08:30
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz® (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.1 Taltz is the first and only...

08:05
Vast Therapeutics, Inc., formerly Novoclem Therapeutics, Inc. (the Company), a preclinical stage pharmaceutical company focused on delivering the power of nitric oxide (NO) in a synthetically derived powder-based form, announced today that the...

08:01
The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1...

08:00
Epic Sciences announced today that new data will be presented from studies utilizing its single cell sequencing of circulating tumor cells (CTCs) to determine differential and mutually exclusive mutational patterns associated with mismatch DNA damage...

07:30
BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia A. The...

07:00
Check-Cap Ltd. (the "Company" or "Check-Cap") , a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule preparation-free, colorectal cancer screening, today announced that the results of its...

05:00
Koios Beverage Corp. (the "Company" or "Koios"), which makes brain healthy beverages that can improve cognitive function, is pleased to announce it has entered into an agreement with NeuraPerformance/Neuroptimize Brain Center whereby...

05:00
Complementary experience offered by the Kenya Medical Research Institute (KEMRI) and the Université Félix Houphouët-Boigny (UFHB) in conducting clinical trials in sub-Saharan Africa will be instrumental for the success of the Consortium's phase III...

02:00
A highly innovative software, developed by Pie Medical Imaging - PMI - B.V. (Esaote Group) will be presented at EuroPCR 2018, the world-leading course in interventional cardiovascular medicine, held in Paris, Palais des Congrès (France) between 22 -...

02:00
Un logiciel hautement innovant, développé par PMI (Pie Medical Imaging B.V.) sera présenté à l'EuroPCR 2018, l'événement de renommée mondiale dans le domaine de la médecine cardiovasculaire interventionnelle qui se tiendra à Paris, au Palais des...

00:28
NMT2  announces it will be featured at the 2018 EUROPCR Congress in Paris, France.  The annual assembly, which again takes place at the Palace de Congress in Paris from May 22-25, 2018, is the worldwide gathering for in-depth scientific...


21 mai 2018

17:52
Viera BioScience announced today positive data demonstrating that its AngioMunetm T Regulatory Cell based product successfully reduced cardiac damage and stimulated production of new blood vessels in animals that were induced to undergo a heart...

16:00
A new head-to-head pharmacokinetic study showed that adults with hemophilia B who received a single dose (50 IU/kg) of Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated] achieved high factor IX activity for longer than those treated with...

14:14
Results showed DUPIXENT demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other...

14:00
Boehringer Ingelheim Pharmaceuticals, Inc. today announced new presentations at the American Thoracic Society's 2018 annual conference that reinforce the efficacy, safety and tolerability profile of Ofev® (nintedanib) in patients with idiopathic...

13:59
Wills Eye Hospital clinician researchers continue on an accelerated research track, digging deeper across the board in all subspecialties of ophthalmology to determine new and better practice patterns in patient care. A number of recent studies have...

13:25
Entrinsic Health Solutions in partnership with the Markey Cancer Center today announced clinical data showing the anti-diarrheal efficacy of enterade® ? a glucose-free, amino acid oral rehydration solution ? in neuroendocrine tumor (NET) patients....

12:19
The Department of Ear Nose & Throat/Allergy at Summit Medical Group was part of a clinical trial that led the U.S. Food & Drug Administration (FDA) to approve XHANCEtm (fluticasone proprionate), a nasal spray for the treatment of nasal polyps in...

12:15
Inari Medical, Inc., announced today the FlowTriever System has received FDA 510(k) clearance for the treatment of pulmonary embolism ("PE"). This clearance makes the FlowTriever System the first and only thrombectomy device cleared by the FDA for...

09:40
The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia. The outcomes were developed and agreed upon by a multi-stakeholder group, through an intensive research and formal consensus...

08:30
Nestlé Skin Health, a global leader focused on meeting the world's increasing skin health needs, announced today that the U.S. Food and Drug Administration (FDA) has approved the hyaluronic acid (HA) dermal filler Restylane® Lyft for the correction...

08:30
Arena Pharmaceuticals, Inc. today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in...

08:00
Genomic Health, Inc.  today announced results from two new studies demonstrating the positive impact of the Oncotype DX® Genomic Prostate Scoretm (GPStm) test on risk assessment for better treatment decisions in clinically low-risk prostate cancer...

08:00
Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first...

07:00
ROCKVILLE, Md. and HONG KONG, May 21, 2018 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results...

07:00
Verge Genomics, a drug discovery company utilizing machine learning to develop new therapeutics, announced today the launch of a groundbreaking initiative to sequence genes expressed in the brains of Parkinson's patients at a single cell resolution,...

07:00
MaxCyte, the global cell-based medicines and life sciences company, today announced that Linghong Li, PhD, Director, Cell Engineering, presented pre-clinical data at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in...

07:00
Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative...

05:45
Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also...

05:18
NeuroVive Pharmaceutical AB  and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock in the phase I single ascending dose (SAD) clinical study of KL1333, a novel...

05:17
A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow, UK....


20 mai 2018

17:15
Today at the American Thoracic Society (ATS) Conference 2018, Royal Philips , a global leader in health technology, announced new data suggesting that combining home oxygen therapy (HOT) with home non-invasive ventilation (HMV) as treatment for...

14:00
A multifaceted approach to treating men with orchialgia and chronic pelvic pain may lead to improvements in quality of life and less pain over time, according to data being presented at the 113th Annual Scientific Meeting of the American Urological...


19 mai 2018

12:30
Researchers will present new findings on a Korean FDA-approved robotic system, safety of testosterone therapy after prostate cancer and active surveillance protocol for low-risk prostate cancer patients at the 113th Annual Meeting of the American...

11:30
Use of magnetic resonance imaging (MRI) in the diagnosis of prostate cancer is increasing, and brings added value to screening and surveillance, according to new studies being presented this year during the 113th Annual Meeting of the American...


18 mai 2018

17:50
The Janssen Pharmaceutical Companies of Johnson & Johnson today presented post-hoc analysis from the Phase 3 SPARTAN study that showed treatment with ERLEADAtm (apalutamide) significantly reduced the risk of prostate specific antigen (PSA)...

14:00
Two new studies examining environmental factors relating to bladder cancer and urinary stone disease will be presented at the 113th Annual Meeting of the American Urological Association (AUA). During a joint press conference at the Moscone Center in...

11:30
New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening will be presented this year during the 113th Annual Meeting of the American...

09:38
Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders today announced a partnership with BrainScope for use of their FDA-cleared...

08:04
Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date Results showed a reduction in both...

08:01
Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the presentation of preliminary data from Zella201, an ongoing Phase 2 study evaluating the...

07:00
Histoindex Pte. Ltd., with the world's first stain-free Genesis®200 multiphoton digital pathology system, is collaborating with CymaBay Therapeutics, Inc. to evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled,...

02:22
This week, dosing was completed according to plan in the second clinical study with Immunosetm FLU, developed with the aim to become a modern and effective nasal influenza vaccine. - In the perspective of this year's severe influenza outburst we...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19